Tango Therapeutics Q2 net loss widens as expenses rise

Tango Therapeutics

11/08/2026 12:08

Overview
US biotechnology firm's Q2 net loss widened yr/yr as expenses rose
Collaboration revenue fell to zero after Gilead partnership ended
Company highlighted positive Phase 1/2 data for vopimetostat in pancreatic cancer

Outlook
Company expects to finalize Phase 3 trial design for vopimetostat combo in pancreatic cancer in 2H 2026
Tango plans to present Phase 1/2 vopimetostat combo data at 2026 ESMO Congress in October
Company expects cash position to fund planned development and commercialization preparation

Result Drivers
R&D SPEND - Increased research and development expenses driven by advancement of vopimetostat and TNG456 clinical programs
ADMIN COSTS - Higher general and administrative expenses due to increased personnel-related costs, including share-based compensation
COLLABORATION REVENUE DROP - Collaboration revenue fell to zero after Gilead partnership ended

Company press release: ID:nGNXbN4jxT

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.37
 
Q2 Net Loss
 
$55.34 mln
 
Q2 Loss Per Basic Share
 
$0.37
 
Q2 Operating Expenses
 
$59.79 mln
 
Q2 Operating Income
 
-$59.79 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Tango Therapeutics, Inc. is $40.00, about 44.6% above its August 10 closing price of $27.67

Reuters Recommended Reads
Aug 11 - Shattuck Labs Q2 net loss widens as R&D spending rises
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)